Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. (EGX:RMDA)
Egypt
· Delayed Price · Currency is EGP 4.400
+0.130 (3.04%)
At close: Mar 27, 2025
EGX:RMDA Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,769 | 1,922 | 1,484 | 1,246 | 960.17 | Upgrade
|
| Revenue Growth (YoY) | 44.03% | 29.54% | 19.06% | 29.81% | 7.41% | Upgrade
|
| Cost of Revenue | 1,487 | 1,018 | 765.28 | 669.61 | 514.34 | Upgrade
|
| Gross Profit | 1,281 | 904.06 | 718.67 | 576.82 | 445.83 | Upgrade
|
| Selling, General & Admin | 558.11 | 444.06 | 360.96 | 303.18 | 258.18 | Upgrade
|
| Other Operating Expenses | -27.3 | -7.34 | -6.04 | -0.76 | -1.16 | Upgrade
|
| Operating Expenses | 558.54 | 458.3 | 376.41 | 302.53 | 258.82 | Upgrade
|
| Operating Income | 722.93 | 445.76 | 342.26 | 274.29 | 187.01 | Upgrade
|
| Interest Expense | -307.21 | -191.2 | -89.07 | -91.03 | -96.64 | Upgrade
|
| Interest & Investment Income | 65.85 | 62.9 | 56.73 | 59.97 | 64.16 | Upgrade
|
| Currency Exchange Gain (Loss) | 56.24 | 18.68 | 25.65 | -0.6 | -1.7 | Upgrade
|
| Other Non Operating Income (Expenses) | -11.7 | -8.84 | -6.99 | -8.31 | -7.58 | Upgrade
|
| EBT Excluding Unusual Items | 526.11 | 327.31 | 328.58 | 234.33 | 145.25 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | 0.14 | -0.13 | -0.72 | -0.14 | Upgrade
|
| Pretax Income | 526.12 | 327.45 | 328.45 | 233.61 | 145.11 | Upgrade
|
| Income Tax Expense | 124.31 | 74.24 | 75.57 | 53.52 | 33.59 | Upgrade
|
| Earnings From Continuing Operations | 401.81 | 253.21 | 252.89 | 180.09 | 111.51 | Upgrade
|
| Minority Interest in Earnings | -14.44 | -8.35 | -7.21 | 1 | 0.67 | Upgrade
|
| Net Income | 387.37 | 244.86 | 245.68 | 181.09 | 112.18 | Upgrade
|
| Preferred Dividends & Other Adjustments | 23.53 | 21.36 | 16.76 | 14.7 | 14.7 | Upgrade
|
| Net Income to Common | 363.84 | 223.5 | 228.91 | 166.39 | 97.48 | Upgrade
|
| Net Income Growth | 58.20% | -0.33% | 35.67% | 61.43% | 36.15% | Upgrade
|
| Shares Outstanding (Basic) | 1,497 | 1,491 | 1,475 | 1,523 | 1,523 | Upgrade
|
| Shares Outstanding (Diluted) | 1,505 | 1,501 | 1,483 | 1,523 | 1,523 | Upgrade
|
| Shares Change (YoY) | 0.23% | 1.27% | -2.62% | - | - | Upgrade
|
| EPS (Basic) | 0.24 | 0.15 | 0.16 | 0.11 | 0.06 | Upgrade
|
| EPS (Diluted) | 0.24 | 0.15 | 0.15 | 0.11 | 0.06 | Upgrade
|
| EPS Growth | 62.39% | -3.56% | 41.28% | 70.69% | 18.31% | Upgrade
|
| Free Cash Flow | -371.85 | -135.54 | -5.03 | 188.68 | -249.31 | Upgrade
|
| Free Cash Flow Per Share | -0.25 | -0.09 | -0.00 | 0.12 | -0.16 | Upgrade
|
| Dividend Per Share | - | 0.067 | - | - | - | Upgrade
|
| Gross Margin | 46.28% | 47.03% | 48.43% | 46.28% | 46.43% | Upgrade
|
| Operating Margin | 26.11% | 23.19% | 23.06% | 22.01% | 19.48% | Upgrade
|
| Profit Margin | 13.14% | 11.63% | 15.43% | 13.35% | 10.15% | Upgrade
|
| Free Cash Flow Margin | -13.43% | -7.05% | -0.34% | 15.14% | -25.96% | Upgrade
|
| EBITDA | 802.33 | 514.61 | 403.67 | 316.61 | 239.55 | Upgrade
|
| EBITDA Margin | 28.98% | 26.77% | 27.20% | 25.40% | 24.95% | Upgrade
|
| D&A For EBITDA | 79.4 | 68.85 | 61.41 | 42.31 | 52.54 | Upgrade
|
| EBIT | 722.93 | 445.76 | 342.26 | 274.29 | 187.01 | Upgrade
|
| EBIT Margin | 26.11% | 23.19% | 23.06% | 22.01% | 19.48% | Upgrade
|
| Effective Tax Rate | 23.63% | 22.67% | 23.01% | 22.91% | 23.15% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.